MS BioNTech WKN: A2PSR2 ISIN: US09075V1026 Forum: Aktien User: Thekla

https://twitter.com/drericding/status/1512989742710898689?s=21&t=HDayNp2NHe4PQL880iKL8w Natürlich duldet die chinesische Regierung kein Balkongesang oder Proteste. Und natürlich erscheint eine Regierungsdrohne: „Bitte halten Sie sich an die COVID-Regeln. ** Kontrolliere das Verlangen deiner Seele nach Freiheit **. Öffne kein Fenster, um zu singen.“ ➡️ Ja, die Drohne hat das tatsächlich gesagt.

Was ist da los…. Achtung Video 😞 Bewohner in #Shanghai schreien nach 7 aufeinanderfolgenden Tagen der Sperrung der Stadt aus Hochhauswohnungen. Der Erzähler befürchtet, dass es große Probleme geben wird. (im Shanghaier Dialekt – er sagt voraus, dass die Menschen nicht mehr lange durchhalten können – er impliziert eine Tragödie). Das Video wurde von der Familie von @patrickmadrid verifiziert. Es wurde auch von meinen Quellen als alltäglich bestätigt. Außerdem ist Shanghainese ein lokaler Dialekt (nicht wirklich propagandatauglich) – nur 14 Millionen von 1,3 Milliarden Chinesen sprechen überhaupt. Ich spreche es nur, weil ich dort geboren bin. Dr Eric Feigl-Ding https://twitter.com/drericding/status/1512974880463114241?s=21&t=HDayNp2NHe4PQL880iKL8w

Wow - da , kann er sich doch drüber freuen - ist doch kostenlose Werbung für Ihn ( siehe Corona Ticker um 14:50)

Ja klingt gut brauch aber Zeit dieich habe.

Habe heute früh schon in deutsch.10.31.uhr.

Q&A Why Do Vaccines Wear Off So Quickly Why do vaccines wear off so quickly? In this week's edition of the Covid Q&A, we look at the waning effectiveness of vaccines. In hopes of making this very confusing time just a little less so, each week Bloomberg Prognosis picks one reader question and puts it to experts in the field. This week’s question comes to us from Ruth in Chicago. She asks: I keep wondering why the Covid vaccine’s effectiveness wanes so quickly. Is it the messenger RNA technology? Something else? The reality of life after vaccination has looked a little different than we imagined. There was that glorious period after vaccines first rolled out when it seemed like the pandemic was at long last over and we could just slip right back into our old pre-Covid lives. SARS-CoV-2, though, is a wily virus. It keeps evolving around our defenses, with new variants like omicron rendering vaccines and treatments less effective. “The situation with the Covid-19 vaccines actually is similar to the situation that we have annually with the flu vaccine,” says Katrine Wallace, an epidemiologist at University of Illinois at Chicago. It’s not that the effectiveness of the shots is wearing off so much as the virus is evolving to be better at evading the first-line defenses of vaccines. “The available vaccines were created for the original 2019 ‘wild-type’ SARS-CoV-2 virus,” says Wallace. “The virus has undergone multiple mutations since then, and several new variants have circulated globally (alpha, beta, delta, omicron). Viruses mutate all the time, and a viral variant occurs when a mutation causes the virus to behave differently, either to become more transmissible, cause more severe disease or cause decreased effectiveness of available vaccines or medications.” In the case of SARS-CoV-2, those mutations have occurred largely on the spike protein, the crown-shaped part of the virus that helps it invade the body’s cells. The spike is also the target of vaccines and other Covid therapies like monoclonal antibody drugs. So as the virus mutates, it gets better at evasion. However, so far the virus has appeared adept only at getting around the first-line defenses of vaccines — that’s why hospital rates and deaths haven’t increased at the same rate of infections, even in the face of the hyper-contagious omicron variant. Other immune defense systems, such as T-cells spurred by vaccines, still appear effective at fighting off Covid. “But even for those endpoints, it is not 100% effective,” says Wallace. “In the case of omicron, it is so transmissible that even with an effective vaccine against severe disease, during large surges we will still see severe cases happening because of the high number of infections.” For that reason, vaccine manufacturers are investigating omicron-specific boosters. At present, immunocompromised people and those over age 50 are eligible in the U.S. for a second booster shot. Just this week, the Food and Drug Administration held a meeting of its panel of outside vaccine experts to discuss future boosters. The main takeaway: There isn’t an obvious answer to when more boosters will be necessary. People often compare Covid with influenza, which also mutates frequently, requiring new flu shots every year. Those flu shots aren’t made with mRNA technology but still are susceptible to viral changes. Also, Wallace points out we have all had a lifetime of exposure to the flu. “A virus can spread and mutate a lot faster within a population of completely susceptible hosts,” she says. Bloomberg https://www.bloomberg.com/news/newsletters/2022-04-10/coronavirus-daily-why-do-vaccines-wear-off-so-quickly?utm_medium=social&cmpid=socialflow-twitter-business&utm_source=twitter&utm_content=business&utm_campaign=socialflow-organic

Du bist zu gütig… 😘😃

📣Kurze Mitteilung: Ihr habt heute 15.30 frei👍 kein Antreten zum Nasdaq Start. Das zum Thema: Strenge Kapitänin👮🏻‍♀️😅

geht doch alles in die richtige Richtung. Man braucht nur noch etwas Geduld :)

Zusammengefasst gute News?! Dann geht's ja morgen runter 🤣 hoffe mal auf das Gegenteil 🍀

Danke lluciman, viel fachliches, das nicht unbedingt übersetzt werden muss, ..... . der Kernsatz , der auch nuxht überraschend und auch keineswegs enttäuschend sein darf für diese Studie Line 1;: Diese Daten befinden sich noch in einem sehr frühen Stadium, in dem nur wenige Patienten behandelt wurden, so dass zum jetzigen Zeitpunkt noch keine wesentlichen Schlussfolgerungen gezogen werden können.

It is remarkable that most of the patients with testicular cancer showed clinical benefit at dose level 2, and the responses we have observed can be deep, including one ongoing complete remission,” said Haanen. “The infusion of CLDN6 CAR T, alone or in combination with CARVac, is safe and holds promise for patients with CLDN6-positive cancers,” Haanen added. “CLDN6 was never targeted before with cellular therapy, but in our study, this approach is already showing efficacy that may be better than the data from other CAR T trials in solid tumors.”

Hier ein Artikel zu den ersten Ergebnissen bzgl BNT211 https://www.miragenews.com/new-car-t-cell-therapy-for-solid-tumors-was-761922/#//

Bin 100% deiner Meinung, liebe Thekla. Natürlich freuen wir uns eines Tages riesig über satte Gewinn - das wird die Belohnung für unsere Geduld, Treue und den Glauben in das Unternehmen sein...🙏☘️🍀